Article

David Alexander on the MPN Heroes Program

David Alexander was selected as an MPN Hero at this year's MPN Heroes event. The MPN Heroes event honors clinicians, caregivers, and advocates who have made significant contributions in the field of myeloproliferative neoplasms (MPNs).

David Alexander was selected as an MPN Hero at this year's MPN Heroes event. The MPN Heroes event honors clinicians, caregivers, and advocates who have made significant contributions in the field of myeloproliferative neoplasms (MPNs).

Alexander, from Washington, D.C., is an advocate who was nominated for his efforts to help patients keep up with the latest research and publications on MPNs and for his role in the online support group MPN-NET. An environmental lawyer and marathon runner, David believes in “the magic of every day.” He is a moderator of MPN-NET whose prodigious postings of technical hematology material bring current scientific knowledge to the MPN community. He was selected as a Hero in the Commitment to the Broader MPN Community.

By sharing the latest scientific findings, David’s goal is to help patients be aware about treatment advances, clinical studies, the nature of risk, and how to use risk to maintain a balanced life with MPNs.

You can learn more about the MPN Heroes at curetoday.com/events/mpn.

Related Videos
Image of woman.
Dr. Andreas M. Kaiser is a professor and chief of the Division of Colorectal Surgery in the Department of Surgery at City of Hope comprehensive cancer center in Duarte, California.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Image of woman with blonde hair.
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the cause, according to research.
Image of woman with black hair.
Image of man with black hair.
Related Content